Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants

Zoonoses and Public Health

Volumn 55, Issue 2, 2008, Pages 99-105

  Hartnack, S ^b,c   Essbauer, S ^d   Truyen, U ^a,c  

^a Vetsuisse ^*  (Germany)

^b VETSUISSE FACULTY UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d BUNDESWEHR INSTITUTE OF MICROBIOLOGY   (Germany)

Author keywords

Chemical disinfection; DVG; Modified vaccinia virus Ankara; RKI DVV; Vaccinia virus Lister Elstree

Indexed keywords

ACETIC ACID; DISINFECTANT AGENT; FORMALDEHYDE; FORMIC ACID; GLUTARALDEHYDE; GLYOXYLIC ACID; HYDROGEN PEROXIDE; PERACETIC ACID;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DISINFECTION; INFECTION RISK; MODIFIED VACCINIA VIRUS ANKARA; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VACCINIA VIRUS; VIRUS ACTIVATION; VIRUS INFECTION; VIRUS STRAIN;

CELLS, CULTURED; DISINFECTANTS; DISINFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; GERMANY; HUMANS; SMALLPOX; SMALLPOX VACCINE; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS;

VACCINIA VIRUS; VACCINIA VIRUS ANKARA; VARIOLA; VARIOLA VIRUS;

EID: 38449108281     PISSN: 18631959     EISSN: 18632378     Source Type: Journal    
DOI: 10.1111/j.1863-2378.2007.01094.x     Document Type: Article

References (36)

1. Altenburger, W., C. P. Süter J. Altenburger, 1989 : Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch. Virol. 105, 15 27.
2. Anonymous, 2000 : Richtlinien zur Prüfung chemischer Desinfektionsmittel für die Veterinärmedizin. Deutsche Veterinärmedizinische Gesellschaft e. V., Gießen.
3. Anonymous, 2005 : Leitlinie der deutschen Vereinigung zur Bekämpfung der Viruskrankheiten e.V. und des Robert-Koch-Instituts zur Prüfung von chemischen Desinfektionsmitteln auf Wirksamkeit gegen Viren in der Humanmedizin. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 48, 1420 1426.
4. Antoine, G., F. Scheiflinger, F. Dorner F. G. Falkner, 1998 : The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other Orthopoxviruses. Virology 244, 365 396.
5. Auckland, C., A. Cowlishaw, D. Morgan E. Miller, 2005 : Reactions to small pox vaccine in naïve and previously-vaccinated individuals. Vaccine 23, 4185 4187.
6. Blanchard, T. J., A. Alcami, A. Panayiota G. L. Smith, 1998 : Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79, 1159 1167.
7. Bray, M., 2003 : Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res. 58, 101 114.
8. Breman, J. G. I. Arita, 1980 : The confirmation and maintenance of smallpox eradication. N. Engl. J. Med. 303, 1263 1273.
9. Carroll, M. W. B. Moss, 1997 : Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman cell line. Virology 238, 198 211.
10. Casey, C. G., J. K. Iskander, M. H. Roper, E. E. Mast, X. J. Wen, T. J. Torok, L. E. Chapman, D. L. Swerdlow, J. Morgan, J. D. Heffelfinger, C. Vitek, S. E. Reef, L. M. Hasbrouck, I. Damon, L. Neff, C. Vellozzi, M. McCauley, R. A. Strikas G. Mootrey, 2005 : Adverse events associated with smallpox vaccination in the United States, January-October 2003. J. Am. Med. Assoc. 294, 2734 2743.
11. Coulibaly, S., P. Brühl, J. Mayrhofer, K. Schmid, M. Gerencer F. G. Falkner, 2005 : The nonreplicating smallpox candidate vaccines defective vaccinia Lister (divvy-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341, 91 101.
12. Drexler, I., K. Heller, B. Wahren, V. Erle G. Sutter, 1998 : Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79, 347 352.
13. Eckart, R. E., E. A. Shry, S. O. Jones, J. E. Atwood J. D. Grabenstein, 2005 : Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am. J. Cardiol. 95, 1252 1255.
14. Engler, R. J. M., J. Kenner D. Y. M. Lebung, 2002 : Smallpox vaccination: risk considerations for patients with atopic dermatitis. J. Allergy Clin. Immunol. 110, 357 365.
15. Gallego-Gomez, J. C., C. Risco, D. Rodriguez, P. Babezas, S. Guerra, J. L. Carrascosa M. Esteban, 2003 : Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J. Virol. 77, 10606 10622.
16. Haim, M., M. Gdalevich, D. Mimouni, I. Ashkenazi J. Shemer, 2000 : Adverse reactions to smallpox vaccine: the Israel Defence Force experience, 1991 to 1996. A comparison with previous surveys. Mil. Med. 165, 287 289.
17. Kemper, A., M. Davis G. Freed, 2002 : Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 5, 84 90.
18. Lewis, F. M. T., E. Chernak, E. Goldman, Y. Li, K. Karem, I. K. Damon, R. Henkel, E. C. Newbern, P. Ross C. C. Johnson, 2006 : Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg. Infect. Dis. 12, 134 137.
19. Mayr, A., A. Bachmann B. Bibrach, 1974 : Virologische Arbeitsmethoden. Gustav Fischer Verlag, Stuttgart.
20. Mayr, A., H. Stickl, H. K. Müller, K. Danner H. Singer, 1978 : The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. [Orig. B] 167, 375 390.
21. Mempel, M., G. Isa, N. Klugbauer, H. Meyer, G. Wildi, J. Ring, F. Hofmann H. Hofmann, 2003 : Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J. Invest. Dermatol. 120, 356 358.
22. Meyer, H., G. Sutter A. Mayr, 1991 : Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72, 1031 1038.
23. Moussatche, N., M. Tuyama, S. E. Kato, A. P. B. Castro, R. H. Peralta, J. M. Peralta, C. R. A. Damaso P. F. Barroso, 2003 : Accidental infection of laboratory worker with vaccinia virus. Emerg. Infect. Dis. 9, 724 726.
24. Ober, B. T., P. Brühl, M. Schmidt, V. Wieser, W. Gritschenberger, S. Coulibaly, H. Savidis-Dacho, M. Gerencer F. G. Falkner, 2002 : Immunogenicity and safety of defective vaccinia virus Lister: comparison with modified vaccinia virus Ankara. J. Virol. 76, 7713 7723.
25. Openshaw, P. J. M., W. H. Alwan, A. H. Cherrie F. M. Record, 1991 : Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 338, 459.
26. Rupprecht, C. E., L. Blass, K. Smith, L. A. Orciari, M. Niezgoda, S. G. Whitefield, R. V. Gibbons, M. Guerra C. A. Hanlon, 2001 : Human infection due to recombinant vaccinia-rabies glycoprotein virus. N. Engl. J. Med. 345, 582 586.
27. Sejvar, J. J., R. K. Labutta, L. E. Chapman, J. D. Grabenstein, J. Iskander J. M. Lane, 2005 : Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. J. Am. Med. Assoc. 294, 2744 2750.
28. Slifka, M. K., 2005 : The future of smallpox vaccination: is MVA the key? Med. Immunol. 4, 2.
29. Stittelaar, K. J., T. Kuiken, R. L. de Swart, G. van Amerongen, H. W. Vos, H. G. M. Niesters, P. van Schalkwijk, T. van der Kwast, L. S. Wyatt, B. Moss A. D. M. E. Osterhaus, 2001 : Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19, 3700 3709.
30. Stittelaar, K. J., G. van Amerongen, I. Kondova, T. Kuiken, R. F. van Lavieren, F. H. M. Pistoor, H. G. M. Niesters, G. van Doornum, B. A. M. van der Zeijst, L. Mateo, P. J. Chaplin A. D. M. Osterhaus, 2005 : Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79, 7845 7851.
31. Sutter, G. B. Moss, 1992 : Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89, 10847 10851.
32. Sutter, G. C. Staib, 2003 : Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3, 263 271.
33. Waibler, Z., M. Anzaghe, H. Ludwig, S. Akira, S. Weiss, G. Sutter U. Kalinke, 2007 : Modified vaccinia virus Ankara induces Toll-like receptor independent type I interferon responses. J. Virol. 81, 12102 12110.
34. Werner, G. T., U. Jentzsch, E. Metzger J. Simon, 1980 : Studies on poxvirus infections in irradiated animals. Arch. Virol. 64, 247 256.
35. Wlodaver, C. G., G. J. Palumbo J. L. Waner, 2004 : Laboratory-acquired vaccinia infection. J. Clin. Virol. 29, 167 170.
36. Wyatt, L. S., P. L. Earl, L. A. Eller B. Moss, 2004 : Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. USA 101, 4590 4595.